UK markets close in 3 hours 39 minutes

Genfit S.A. (0QT6.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
3.2900-0.0775 (-2.30%)
As of 12:00PM GMT. Market open.
Full screen
Previous close3.3675
Open3.2900
Bid3.1900 x 0
Ask3.3500 x 0
Day's range3.2900 - 3.2900
52-week range2.8400 - 4.9000
Volume0
Avg. volume12,598
Market cap175.558M
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-0.6700
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    GENFIT Announces 2024 Financial Calendar

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024. 2024 Financial Calendar February 29, 2024 Publication of revenue and cash position at December 31, 2023 April 4, 2024 Publication of Full Year 2023 financial statements The

  • GlobeNewswire

    GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland) January 11, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial. Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity accoun

  • GlobeNewswire

    GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

    US Food and Drug Administration (FDA) has granted Priority Review for New Drug Application (NDA) for elafibranor in PBC, and European Medicine Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor.Acceptance triggers a first milestone payment. Further milestones are expected upon US and European launches which could now happen in 2Q24 in the US (FDA PDUFA1 action date: June 10, 2024) and 2H24 in Europe. These milestones total approximately 89M€. Launches i